Esperion (ESPR) announced that it has entered into a settlement agreement with Dr. Reddy’s Laboratories (RDY) and its affiliate Dr. Reddy’s Laboratories. This agreement resolves the patent litigation brought by Esperion against Dr. Reddy’s Laboratories in response to Dr. Reddy’s Laboratories’ Abbreviated New Drug Application, ANDA, seeking approval to market a generic version of each of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Dr. Reddy’s Laboratories has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion management to meet with Cantor Fitzgerald
- Esperion price target raised to $9 from $7 at Cantor Fitzgerald
- Esperion’s US Market Stagnation Overshadows Japanese Approval, Justifying Sell Rating
- Esperion’s Strategic Milestone: Nexletol Approval in Japan Boosts Financial Outlook with $120 Million Potential
- Esperion’s Strategic Advancements: Regulatory Approval and Market Expansion Boost